U.S. patent application number 11/981198 was filed with the patent office on 2008-03-27 for pulmonary delivery of active fragments parathyroid hormone.
Invention is credited to John S. Patton.
Application Number | 20080075782 11/981198 |
Document ID | / |
Family ID | 25493936 |
Filed Date | 2008-03-27 |
United States Patent
Application |
20080075782 |
Kind Code |
A1 |
Patton; John S. |
March 27, 2008 |
Pulmonary delivery of active fragments parathyroid hormone
Abstract
Systemic delivery of parathyroid hormone to a mammalian host is
accomplished by inhalation through the mouth of a dispersion of an
N-terminal fragment of PTH. It has been found that such respiratory
delivery of the PTH fragment provides a pulsatile concentration
profile of the PTH in the host's serum. PTH fragment compositions
include dry powder formulations having the PTH present in a dry
bulking powder, liquid solutions or suspensions suitable for
nebulization, and aerosol propellants suitable for use in a metered
dose inhaler.
Inventors: |
Patton; John S.; (San
Franciso, CA) |
Correspondence
Address: |
NEKTAR THERAPEUTICS
201 INDUSTRIAL ROAD
SAN CARLOS
CA
94070
US
|
Family ID: |
25493936 |
Appl. No.: |
11/981198 |
Filed: |
October 30, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10245707 |
Sep 18, 2002 |
7300919 |
|
|
11981198 |
Oct 30, 2007 |
|
|
|
09577264 |
May 22, 2000 |
|
|
|
10245707 |
Sep 18, 2002 |
|
|
|
09128401 |
Aug 3, 1998 |
6080721 |
|
|
09577264 |
May 22, 2000 |
|
|
|
08625586 |
Mar 28, 1996 |
5814607 |
|
|
09128401 |
Aug 3, 1998 |
|
|
|
08232849 |
Apr 25, 1994 |
5607915 |
|
|
08625586 |
Mar 28, 1996 |
|
|
|
07953397 |
Sep 29, 1992 |
|
|
|
08232849 |
Apr 25, 1994 |
|
|
|
Current U.S.
Class: |
424/489 ;
514/11.8; 514/16.9; 514/772; 514/777 |
Current CPC
Class: |
A61K 9/0075 20130101;
A61P 43/00 20180101; A61K 9/008 20130101; A61P 19/10 20180101; A61P
3/00 20180101; A61K 9/0078 20130101; A61K 9/0073 20130101; A61P
5/18 20180101; A61K 38/29 20130101 |
Class at
Publication: |
424/489 ;
514/012; 514/772; 514/777 |
International
Class: |
A61K 38/29 20060101
A61K038/29; A61K 47/10 20060101 A61K047/10; A61K 47/26 20060101
A61K047/26; A61K 9/14 20060101 A61K009/14; A61P 5/18 20060101
A61P005/18 |
Claims
1. A therapeutic dried composition in solid dose form suitable for
transmucosal delivery, comprising a stabilizing polyol and a
bioactive agent wherein the composition provides quick release of
the bioactive agent after administration.
2. The composition, according to claim 1, wherein the composition
is freeze-dried, vacuum-dried, or spray-dried.
3. The composition, according to claim 1, wherein the bioactive
agent is a pharmaceutical agent, a hormone, a hormone fragment, a
hormone analog, or a combination of any of the foregoing.
4. The composition of claim 1 wherein the stabilizing polyol
comprises a monosaccharide.
5. The composition of claim 1 wherein the composition comprises a
powder.
6. The composition of claim 5 wherein the powder comprises a
particle size range of about 0.5 microns to about 5 microns.
7. The composition of claim 1 wherein the delivery comprises
pulmonary or respiratory administration.
8. The composition according to claim 7, wherein said pulmonary or
respiratory administration results in a pulsatile serum
concentration profile characterized by a rapid rise to a peak and
followed by a rapid fall.
9. A therapeutic composition in liquid form suitable for pulmonary
or respiratory delivery, comprising a buffer and a bioactive agent
wherein the composition provides quick release of the bioactive
agent and a high level of bioavailability after administration.
10. The composition, according to claim 9, wherein the buffer is an
organic acid.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of application Ser. No.
10/245,707, filed Sep. 18, 2002, which application is a
continuation of application Ser. No. 09/577,264, filed May 22,
2000, which application is a continuation of application Ser. No.
09/128,401, filed Aug. 3, 1998, now issued as U.S. Pat. No.
6,080,721, which application is a divisional of application Ser.
No. 08/625,586; filed on Mar. 28, 1996, now issued as U.S. Pat. No.
5,814,607, which application is a continuation of application Ser.
No. 08/232,849; filed Apr. 25, 1994, now issued as U.S. Pat. No.
5,607,915, which application is a continuation of application Ser.
No. 07/953,397; filed Sep. 29, 1992, now abandoned, the full
disclosures of which are incorporated herein by reference.
BACKGROUND OF THE INVENTION
[0002] The present invention relates generally to methods and
compositions for systemic administration of parathyroid hormone to
mammalian hosts. More particularly, the present invention relates
to pulmonary administration of active parathyroid hormone fragments
to provide pulsatile serum concentration profiles.
[0003] Human parathyroid hormone (PTH) is an 84 amino acid protein
that is involved in calcium and phosphorus homeostasis and control
of bone growth and density. N-terminal fragments of PTH,
particularly those consisting of amino acids 1-34 and 1-38, retain
the full biological activity of the intact protein. Recently, the
use of PTH and PTH fragments in combination with vitamin D or
dietary calcium was found to be effective in the treatment of
osteoporosis when administered to a host on a periodic, preferably
daily, basis.
[0004] Heretofore, the administration of PTH and PTH fragments has
generally been accomplished subcutaneously, i.e., through
injection. The need to inject PTH (or any other drug) on a daily
basis, however, is undesirable. Most patients have an aversion to
self-injection of drugs, and the need to visit a clinic or doctor's
office for administration is inconvenient and burdensome. While
other forms of administration have been suggested, such as oral
delivery to the stomach, transdermal delivery, and nasopharyngeal
absorption, none of these delivery routes has been proven to be
effective and each suffers from certain drawbacks. Oral delivery
results in very low bioavailability of polypeptide drugs, usually
below 1%, due to degradation in the gastrointestinal tract.
Moreover, the epithelial lining of the gastrointestinal tract is
impermeable to most polypeptides. Nasopharyngeal and transdermal
delivery avoid the problems of enzyme degradation, but usually
require penetration enhancers in order to effect systemic
absorption. Even with such penetration enhancers, bioavailability
will usually be very low, and the penetration enhancers can often
cause undesirable irritation. In the case of nasopharyngeal
administration, penetration enhancers can often damage the nasal
epithelium and chronic use has been associated with hyperplasia of
the nasal lining.
[0005] Pulmonary or respiratory delivery of polypeptide drugs has
also been suggested. Relatively large proteins, such as growth
factors and cytokines which are typically larger than 150 amino
acids, are often readily absorbed through the cellular lining of
the alveolar region of the mammalian lung. Advantageously, such
absorption can be achieved without the use of penetration
enhancers. The pulmonary absorption of smaller proteins, usually
below 100 amino acids in length, is much less predictable. Many
smaller native polypeptides are not absorbed by the mammalian lung,
but certain examples such as insulin (51 amino acids) and
calcitonin (32 amino acids) have been found to be systemically
absorbed when delivered to the lung. Even when a protein drug is
systemically absorbed by a host through the lung, the
pharmacological kinetics of the drug are unpredictable. Thus, both
the amount and timing of drug bioavailability are
unpredictable.
[0006] It is presently believed that PTH is most effectively
delivered to a patient in a pulsatile fashion. That is, serum
concentrations of PTH should rise rapidly after administration and
fall rapidly after a peak has been reached, generally resulting in
a spike in the serum concentration profile. Thus, it is
advantageous for any route of PTH delivery to provide such a serum
concentration profile.
[0007] For these reasons, it would be desirable to provide
alternative delivery methods for parathyroid hormone which are
patient acceptable. Such methods should avoid subcutaneous
injection, limit irritation to the skin and body mucosa, and
provide a desired pulsatile delivery profile discussed above. Such
methods should further provide for high levels of PTH
bioavailability, be amenable to self-administration by the patient,
and be economic.
[0008] U.S. Pat. Nos. 4,333,125 and 4,698,328, describe the
administration of active parathyroid hormone fragments in
combination with vitamin D or a dietary calcium supplement.
Suggested administration routes include parenteral by injection,
rapid infusion, nasopharyngeal absorption, dermal absorption, or
oral. See also, Neer et al. (1987) Osteoporosis 53:829-835. U.S.
Pat. No. 5,011,678, describes the use of amphophilic steroids as a
penetration enhancer for nasal or bronchopulmonary delivery of
proteins and polypeptides, listing parathyroid hormone as one of a
"veritable host" of proteins which could be delivered with the
enhancer. Parathyroid hormone (full length) is secreted naturally
from the carathyroid gland as a series of spikes in a pulsatile
fashion which is analogous to pituitary hormones (Harms et al.
(1987) Int. Symp. on Osteoporosis, Aalborg, Abstract 232). The full
length hormone is rapidly broken down in the circulation to several
fragments which are the dominant serum forms. It is hypothesized
that an intermittent or pulsatile secretion pattern or parathyroid
hormone is necessary to maintain its bone restoring properties
(Hesch et al. (1988) Calcif. Tissue Int. 42:341-344 and Habener et
al. (1971) Proc. Natl. Acad. Sci. USA 63:2986-2991). Patton and
Platz (1992) Adv. Drug Deliver. Rev. 8:179-196. describe methods
for delivering proteins and polypeptides by inhalation through the
deep lung.
SUMMARY OF THE INVENTION
[0009] According to the present invention, methods and compositions
for the systemic delivery of parathyroid hormone (PTH) to a
mammalian host, particularly a human patient suffering from or at
risk of osteoporosis, provide for a preferred pulsatile
concentration profile of the PTH in the host's serum after
administration. In particular, the methods of the present invention
rely on pulmonary or respiratory delivery of a biologically active
N-terminal fragment of PTH, where delivery of the fragment through
the alveolar region of the lung results in a rapid concentration
spike of PTH in the host serum followed by a quick decrease in
concentration. Surprisingly, pulmonary delivery of intact PTH
protein under the same conditions will result in a relatively
constant serum concentration of PTH over an extended time period.
The ability to obtain the desired pulsatile serum concentration
profile by pulmonary delivery of the PTH fragments, in contrast to
the delivery of intact PTH, could not have been predicted with any
degree of certainty prior to the work reported herein.
[0010] According to an exemplary embodiment, the method of the
present invention comprises dispersing a preselected amount of the
PTH fragment in a volume of gas to produce an aerosolized bolus.
The PTH fragment usually consists of the N-terminal 34 or 38 amino
acids of the PTH molecule but may be an N-terminal fragment of any
size which display the desired pharmacokinetic profile, usually
being 50 or fewer amino acids), and the dispersion may be produced
by introducing a dry powder of the fragment into a high velocity
gas stream, by nebulizing a liquid solution or suspension of the
fragment, or by releasing a propellant containing the PTH fragment
through a nozzle. The patient then inhales the aerosolized bolus
through the mouth and into the alveolar region of the lungs. By
repeating the dispersing and inhaling steps a sufficient number of
times, a desired total dosage of the PTH fragment can be delivered
to the patient.
[0011] Pharmaceutical compositions according to the present
invention include dry powder formulations where the PTH fragment is
present as a powder having a mean particle size in the range from
0.5 mu.m to 5 mu.m in a pharmaceutically acceptable dry bulking
powder, where the PTH is present at from 1% to 10%. A
pharmaceutical composition suitable for nebulization comprises the
biologically active fragment of PTH present in an aqueous buffer at
pH 4-6 in a concentration in the range from 1 mg/ml to 20 mg/ml.
Pharmaceutical compositions suitable or propellant dispersion
comprise a powder of the PTH having a mean particle size in the
range from 0.5 mu.m to 5 mu.m present in an aerosol propellant.
[0012] In addition to the preferred pulsatile pharmacokinetic serum
profile of the PTH fragments, the methods and compositions of the
present invention provide a high level of patient acceptability.
PTH administration does not require injection and can be
self-administered by the patient on a daily basis, usually without
complications such as those associated with transdermal and intra
nasal delivery. The methods and compositions of the present
invention also provide for a high level bioavailability of the PTH,
and are economic.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] FIG. 1 is a graph illustrating the serum profile over time
of PTH34 administered intravenously and intratracheally to rats, as
described in detail in the Experimental section hereinafter.
[0014] FIG. 2 is a grace illustrating the serum profile of PTH84
administered intravenously and intratracheally to rats, as
described in detail in the Experimental section hereinafter.
DESCRIPTION OF SPECIFIC EMBODIMENTS
[0015] Parathyroid hormone (PTH) is delivered to a mammalian host
by inhalation into the alveolar region of the host's lungs. The
cellular lining of the deep mammalian lung is extremely thin (0.1
mu.m) and has been found to be naturally permeable to both full
length PTH and certain biologically active and N-terminal fragments
of PTH, as described below. Surprisingly, however, such pulmonary
or respiratory delivery of the PTH fragments only (and not the full
length PTH) has been found to provide a desired pulsatile serum
concentration profile of the PTH, as is believed to enhance the
biological activity of the PTH, particularly when treating
osteoporosis.
[0016] Thus, the present invention provides for the pulmonary or
respiratory delivery of biologically active N-terminal fragments of
PTH by inhalation by a patient through the mouth, where such
fragments have a size which is less than that of full size native
human PTH (human PTH is 84 amino acids) and which results in a
pulsatile serum concentration profile characterized by a rapid rise
to a peak and followed by a rapid fall. The PTH fragments will
preferably be fragments of human PTH (or recombinantly produced
polypeptides having the sequence of human PTH), typically including
up to about 50 amino acids from the N-terminus of the PTH molecule,
more preferably consisting of either amino acids 1-34 or amino
acids 1-38 of human PTH, as set forth in Table 1 below.
[0017] Useful biologically active fragments of PTH also include
chemically modified parathyroid hormone fragments which retain the
activity associated with parathyroid hormone. The necessary
activity is the stimulation of bone formation. Modifications that
may be considered include:
[0018] (1) PTH fragments with carboxyl amino acid extensions beyond
position 34 (but usually not beyond position 50) of the human PTH
molecule, or aminoterminal extensions, or amino acid substitutions
that produce other desirable features, such as an alpha-carboxyl
amide at the carboxyl terminus. A desirable modification would
enhance activity in vivo.
[0019] (2) PTH fragments extended to include amino acids 1-38,
which would enhance receptor binding and hence the activity per
mole.
[0020] (3) PTH fragments chemically modified so as to enhance
through absorption through the alveolar region of the lung.
[0021] (4) Physiologically acceptable salts and esters of PTH
fragments.
[0022] A PTH fragment obtainable from a mammal is generally
preferred over other types of parathyroid hormone fragments, such
as derivatives. Use of a PTH fragment consisting of the first
thirty-four amino acid residues of human parathyroid hormone
(hereafter abbreviated "PTH-34") is especially preferred for use in
humans. Other preferred PTH fragments are those which display some
or all of the following desirable features: increased potency with
regard to the necessary activity, increased ease of administration,
increased selectivity to decrease potential side effects, and
decreased antigenicity in humans to avoid an adverse immune
response. PTH fragments molecules having the sequences 1-34 or 1-38
of Table 1 are particular preferred: TABLE-US-00001 TABLE 1 1 5
H2N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His 10 15
Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu 20 25
Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln 30 35
Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-COOH
[0023] The preferred PTH34 and PTH38 fragments may be obtained
commercially from suppliers such as Peninsula Laboratories, Inc.,
Belmont, Calif.; Sigma Chemical Co., St. Louis, Mo.; Bachem Calif.,
Torrance, Calif.; and others. Alternatively, the PTH fragments may
be produced recombinantly by expression in cultured cells of
recombinant DNA molecules encoding the desired fragment of the PTH
molecule. Suitable recombinant expression systems and methods are
well described in the literature. See, or example, Manniatis,
Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, N.Y.,
1982. The DNA molecules which are expressed may themselves be
synthetic or derived from a natural source. Synthetic
polynucleoctides may be synthesized by well-known techniques, for
example, single-stranded DNA fragments may be prepared by the
phosphoraminite method first described by Beaucage and Carruthers
(1981) Tett. Lett. 22:1859-1862. A double-stranded fragment may
then be obtained either by synthesizing the complementary strand
and annealing the strands together under appropriate conditions, or
by adding the complementary strand using DNA polymerase with an
appropriate primer sequence. The preparation of synthetic DNA
sequences is conveniently accomplished using automated equipment
available from suppliers, such as Applied Biosystems, Inc., Foster
City, Calif.
[0024] The PTH fragments will be formulated in pharmaceutically
acceptable compositions suitable for pulmonary or respiratory
delivery to a mammalian host, usually a human host at risk of or
suffering from osteoporosis. Particular formulations include dry
powders, liquid solutions or suspensions suitable for nebulization,
and propellant formulations suitable for use in metered dose
inhalers (MDI's). The preparation of such formulations is well
described in the patent, scientific, and medical literatures, and
the following descriptions are intended to be exemplary only.
[0025] Dry powder formulations will typically comprise the PTH
fragment in a dry, usually lyophilized, form with a particle size
within a preferred range for deposition within the alveolar region
of the lung, typically from 0.5 mu.m to 5 mu.m. Respirable powders
of PTH fragments within the preferred size range can be produced by
a variety of conventional techniques, such as jet-milling,
spray-drying, solvent precipitation, and the like. Dry powders can
then be administered to the patient in conventional dry powder
inhalers (DPI's) that use the patient's inspiratory breath through
the device to disperse the powder or in air-assisted devices that
use an external power source to disperse the powder into an aerosol
cloud. A particularly useful dry powder disperser is described in
copending application Ser. No. 07/910,048, assigned to the assignee
of the present invention, the full disclosure of which is
incorporated herein by reference.
[0026] Dry powder devices typically require a powder mass in the
range from about 1 mg to 10 mg to produce a single aerosolized dose
("puff"). Since the required dose of PTH fragment will generally be
much lower than this amount, as discussed below, the PTH powder
will typically be combined with a pharmaceutically acceptable dry
bulking powder, with the PTH present usually at from about 1% to
10% by weight. Preferred dry bulking powders include sucrose,
lactose, trehalose, human serum albumin (HSA), and glycine. Other
suitable dry bulking powders include cellobiose, dextrans,
maltotriose, pectin, sodium citrate, sodium ascorbate, mannitol,
and the like. Typically, suitable buffers and salts may be used to
stabilize the PTH fragments in solution prior to particle
formation. Suitable buffers include phosphate, citrate, acetate,
and tris-HCl, typically at concentrations from about 5 mM to 50 mM.
Suitable salts include sodium chloride, sodium carbonate, calcium
chloride, and the like. Other additives, such as chelating agents,
peptidase inhibitors, and the like, which would facilitate the
biological activity of the PTH fragment once it is dissolved within
the lung would be appropriate. For example,
ethylenediaminetetraacetic acid (ETDA) would be useful as a
chelator for divalent cations which are peptidase cofactors.
[0027] Liquid formulations of PTH fragments for use in nebulizer
systems can employ slightly acidic buffers (pH 4-6) with PTH
concentrations of from about 1 mg/ml to 20 mg/ml. Suitable buffers
include acetate, ascorbate, and citrate, at concentrations of 5 mM
to 50 mM. These buffers can act as antioxidants, or other
physiologically acceptable antioxidants can be added to protect
free methionines in the PTH fragment against oxidation. Other
components may be added to enhance or maintain chemical stability,
including chelating agents, protease inhibitors, isotonic
modifiers, inert gases, and the like. A preferred type of nebulizer
suitable for delivering such liquid formulations is described in
copending application Ser. No. 07/910,048, the disclosure of which
has previously been incorporated herein by reference.
[0028] For use in MDI's, the PTH fragments of the present invention
will be dissolved or suspended in a suitable aerosol propellant,
such as chlorofluorocarbon (CFC) or hydrofluorocarbon (HFC).
Suitable CFC's include trichloromonofluoromethane (propellant 11),
dichlorotetrafluoromethane (propellant 114), and
dichlorodifluoromethane, (propellant 12). Suitable HFC's include
tetrafluoroethane (HFC-134a) and heptafluoropropane (HFC-227).
[0029] Preferably, for incorporation into the aerosol propellant,
the PTH fragments of the present invention will be processed into
respirable particles as described for the dry powder formulations.
The particles are then suspended in the propellant, typically being
coated with a surfactant to enhance their dispersion. Suitable
surfactants include oleic acid, sorbitan trioleate, and various
long chain diglycerides and phospholipids.
[0030] Such aerosol propellant formulations may further include a
lower alcohol, such as ethanol (up to 30% by weight) and other
additives to maintain or enhance chemical stability and
physiological acceptability.
[0031] Pulmonary or respiratory administration of PTH fragments
according to the present invention will be useful in the treatment
of osteoporosis, where the PTH fragment will be administered in
combination with vitamin D calcitonin, and/or dietary calcium
supplements. Such treatment methods are well described in U.S. Pat.
Nos. 4,698,328 and 4,833,125, the disclosures of which have
previously been incorporated herein by reference.
[0032] The total aerosolized dosage of PTH fragment for the
treatment of osteoporosis will typically be in range from about
100.mu.g to 2,000.mu.g per day, usually being in the range from
about 250.mu.g to 1000.mu.g per day. Such dosages will result in a
total systemic availability (i.e., amount which is delivered to the
blood) in the range from about 50.mu.g to 500.mu.g per day, usually
from 100.mu.g to 250.mu.g, per day. Precise dosages will, of
course, vary depending on the activity of the particular PTH
fragment or analog employed, and other known pharmacokinetic
factors. Usually, the total dosage of PTH fragment will be
delivered in a plurality of separate aerosolized doses, typically
being at least two and, often being from three to ten, where each
aerosolized bolus contains from 50.mu.g to 500.mu.g of the PTH
fragment.
[0033] Pulmonary delivery of PTH fragments according to the methods
of the present invention has been found to provide a desired
pulsatile serum concentration profile. The pulsatile serum PTH
fragment concentration profile will typically peak within 30
minutes after administration, with serum concentrations falling
rapidly, typically to below 50% of maximum within 30 minutes of the
peak and to below 25% within 60 minutes of the peak.
[0034] In the case of a dry powder formulation, a sufficient amount
of dry bulking powder will be added so that a total dosage of PTH
fragment within the above range can be achieved with one or more
aerosolized boluses which are to be inhaled by the patient.
Typically, the active PTH fragment will be present at from about 1%
to 25% by weight of the powder, with aerosolized boluses including
from 1 mg to 10 mg of the powder. Liquid formulations suitable for
use in nebulizers typically have a concentration of the PTH
fragment in the range from about 1 mg/ml to 20 mg/ml, with the
total volume of nebulized liquid needed to deliver the bolus in the
range from about 0.1 ml to 1 ml. The aerosol propellant
formulations will be delivered by MDI at about 0.5 mg to 5 mg of
PTH fragment per aerosol dose. Because of the inefficiencies of MDI
devices, only a small portion, typically in the range of 5% to 20%,
of the drug will reach the lungs. Thus, a sufficient amount of the
PTH fragment can be delivered in from two to five aerosolized
boluses, with about 1 mg of the PTH fragment in each of the
boluses.
[0035] The following examples are offered by way of illustration,
not by way of limitation.
EXPERIMENTAL
Materials and Methods
[0036] Recombinant human parathyroid hormone (PTH84) was obtained
from Peninsula Laboratories, Inc., Belmont, Calif. (Lot No. 800929)
A recombinant fragment (amino acids 1-34) of human parathyroid
hormone (PTH34) was obtained from Sigma Chemical Co., St. Louis,
Mo. (Lot No. 098F48052).
[0037] Rats (approximately 300-320 g) were obtained from Simonsone
Labs, Gilroy, Calif.
[0038] PTH84 and PTH34 were administered to rats intravenously (IV)
and intratracheally (IT) suspended in 100.mu.l of 20 mM citrate
buffer, pH 5. Dosages were 5.mu.g for IV administration of PTH84,
100.mu.g for IT administration of PTH84, 25.mu.g for IV
administration of PTH34, and 100.mu.g for IT administration of
PTH34.1T administration was performed by making a one inch incision
in the medial neck region and exposing the trachea. The polypeptide
suspensions were injected into the trachea using a tuberculin
syringe with a 30 gauge needle over approximately one minute. The
head of the rat was held upright during the intratracheal injection
and for one additional minute thereafter.
[0039] Rat serum was assayed for PTH34 at periodic intervals after
PTH34 administration using a Nichols Instrument INS PTH assay kit
which measures PTH34 with no cross-reactivity to PTH28-54,
PTH44-68, and PTH53-84. Samples were diluted as necessary to obtain
measurable concentrations.
[0040] Rat serum was assayed for PTH84 with Nichols Instrument
Alegro assay kit for human PTH which measures PTH84 with no
cross-reactivity with PTH34, PTH39-68, PTH44-68, PT53-84, and
PTH39-84. Samples were diluted as necessary to obtain measurable
concentrations.
RESULTS
[0041] The serum profiles of PTH34 and PTH84 in rats following IV
and IT administration are shown in FIGS. 1 and 2, respectively. The
absolute bioavailability of PTH34, which indicates the percentage
of total administered hormone that got into the blood, was about
40%. The absorption profile of PTH34 exhibited a spike at 15
minutes with activity diminishing rapidly thereafter. This is
similar to the profile seen after subcutaneous injection. In
contract, PTH84 at the same intratracheal dose, exhibited a very
different absorption profile. Instead of a spike, a plateau in
serum levels occurred that did not diminish significantly during
the 90 minutes of the experiment. The bioavailability of PTH84 at
90 minutes was about 23% (as measured by the truncated area under
the curve up to 90 minutes), but the slow sustained release
absorption profile suggests that serum levels would have persisted
for longer times.
[0042] Although the foregoing invention has been described in
detail for purposes of clarity of understanding, it will be obvious
that certain modifications may be practiced within the scope of the
appended claims.
Sequence CWU 1
1
1 1 38 PRT Artificial Sequence parathyroid hormone (PTH) fragment
molecues 1 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His
Leu Asn 1 5 10 15 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu
Gln Asp Val His 20 25 30 Asn Phe Val Ala Leu Gly 35
* * * * *